The most frequent actionable alterations are IDH1/2 gain of function mutations and FGFR2 fusions/rearrangements, found in around 5–36% and 8–25%, respectively, of CC cases, mostly ICC. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.